HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Time For NDI Guidance Comment: Health And Wellness Industry News Roundup

This article was originally published in The Rose Sheet

Executive Summary

Testing lapse prompts Sammy's Milk recall; Hain Celestial solves UK trade authority puzzle; scheduling kratom impact calculated; and more news in brief.

You may also be interested in...



DEA Takes Comments On Kratom, But Keeps Eye On Scheduling

DEA will accept comments through Dec. 1 on its proposal to move the active materials in kratom into Schedule I under CSA to avoid an imminent hazard to public safety.

Kratom Reprieve From Scheduling Requested By House Members

Members headed by Reps. Mark Pocan, D-WI, and Matt Salmon, R-AZ, say the proposal was made without allowing opportunity for comment by experts, supplement industry stakeholders and consumers.

Revised NDI Notification Draft Guidance Shrinks Divide Between FDA And Industry

More than four years after beginning to revise its widely criticized initial draft guidance on NDI notifications, FDA on Aug. 11 released a second draft. "I think it is reflective of a new effort by the agency to have a dialogue with the industry," says Steve Mister, president and CEO of the Council for Responsible Nutrition.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel